
    
      Comparative interventional prospective phase 2, randomised, open-label, multicentric trial
      comparing the combination of regorafenib and irinotecan (REGIRI) to irinotecan alone (IRI) as
      second line treatment of patients with metastatic gastro-oesophageal adenocarcinomas.
    
  